论文部分内容阅读
目的 评价羟基喜树碱(HCPT)在肿瘤介入治疗中的应用价值。方法 采用Seldinger’s插管成功后行肿瘤供血动脉灌注化疗共3-10次,部份病例同时行碘化油或明胶海绵栓塞治疗。结果 单药组及联合用药组疗效分别为:原发性肝癌41.67％、43.97％,肺癌57.14％、61.78％,肝转移癌66.67％、76.19％;副作用分别为白细胞、血小板减少9.09％、6.93％,恶心、呕吐72.73％、72.66％,腹泻4.55％、0.61％,单药组尿路刺激症状13.64％。联合用药组对肾癌、膀胱癌、直肠癌、胃癌疗效明显。结论 HCPT在肿瘤介入治疗中具有价廉、效高、抗癌谱广、无交叉耐药、副作用少而轻等优点,对局部组织无刺激作用,联合用药扩大了HCPT应用范围。
Objective To evaluate the value of hydroxycamptothecin (HCPT) in interventional therapy of tumor. Methods The successful use of Seldinger’s intubation after tumor-infusing artery infusion chemotherapy for 3-10 times, in some cases at the same time iodized oil or gelatin sponge embolization. Results The curative effects of single drug group and combined drug group were 41.67% and 43.97% for primary liver cancer, 57.14% and 61.78% for lung cancer, 66.67% and 76.19% for liver metastases, respectively. The side effects were white blood cells, thrombocytopenia 9.09% and 6.93% , Nausea, vomiting 72.73%, 72.66%, diarrhea 4.55%, 0.61%, single group urinary tract irritation 13.64%. Combined treatment group of kidney cancer, bladder cancer, rectal cancer, gastric cancer significantly. Conclusions HCPT has the advantages of low cost, high efficiency, wide spectrum of anti-cancer, no cross-resistance and few side effects in tumor interventional therapy. It has no stimulation to local tissues and the combination of HCPT and HCPT has widened the scope of application of HCPT.